Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An unicenter feasibility study of Pixantrone ontaining R-Cpop as first-line treatment for patients with Aggressive B Cell Lymphoma with Congestive Heart Failure or at Risk of Anthracycline Induced Cardiotoxicity

Trial Profile

An unicenter feasibility study of Pixantrone ontaining R-Cpop as first-line treatment for patients with Aggressive B Cell Lymphoma with Congestive Heart Failure or at Risk of Anthracycline Induced Cardiotoxicity

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2018

At a glance

  • Drugs Pixantrone (Primary) ; Cyclophosphamide; Prednisolone; Rituximab; Vincristine
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Jul 2018 New trial record
    • 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top